Moderna says late-stage trial shows its COVID-19 vaccine is nearly 95 percent effective


Moderna announced early Monday that, according to preliminary phase-three trial data reviewed by an independent monitoring board, its coronavirus vaccine candidate was more than 94 percent effective. CEO Stéphane Bancel called the results a "game-changer." Among the trial's 30,000 participants, 90 COVID-19 cases were found among those getting placebo shots, and only five cases occurred among those who got the two-dose vaccine. Moderna also said doses of its vaccine, once thawed, could last at refrigerated temperatures for a longer-than-expected 30 days.
The vaccine's preliminary 94.5 percent efficacy is a "really important milestone," Moderna president Dr. Stephen Hoge told The Associated Press. But more importantly, the fact that both it and Pfizer's vaccine had similar results "should give us all hope that actually a vaccine is going to be able to stop this pandemic and hopefully get us back to our lives." The company said it expects to seek emergency authorization use from the Food and Drug Administration by early December, once more data has come in.
Pfizer announced last week that its COVID-19 vaccine, developed with BioNTech, was 90 percent effective in phase three trials. The better-than-expected vaccine data arrived as the total number of U.S. infections surpassed 11 million. Michigan and Washington state on Sunday became the latest states to announce broad new restrictions on private gatherings and many businesses to fight the latest wave in the pandemic.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Markets notch worst quarter in years as new tariffs loom
Speed Read The S&P 500 is on track for its worst month since 2022 as investors brace for Trump's tariffs
By Peter Weber, The Week US
-
Tesla Cybertrucks recalled over dislodging panels
Speed Read Almost every Cybertruck in the US has been recalled over a stainless steel panel that could fall off
By Justin Klawans, The Week US
-
Crafting emporium Joann is going out of business
Speed Read The 82-year-old fabric and crafts store will be closing all 800 of its stores
By Peter Weber, The Week US
-
Trump's China tariffs start after Canada, Mexico pauses
Speed Read The president paused his tariffs on America's closest neighbors after speaking to their leaders, but his import tax on Chinese goods has taken effect
By Peter Weber, The Week US
-
Chinese AI chatbot's rise slams US tech stocks
Speed Read The sudden popularity of a new AI chatbot from Chinese startup DeepSeek has sent U.S. tech stocks tumbling
By Peter Weber, The Week US
-
US port strike averted with tentative labor deal
Speed Read The strike could have shut down major ports from Texas to Maine
By Peter Weber, The Week US
-
Biden expected to block Japanese bid for US Steel
Speed Read The president is blocking the $14 billion acquisition of U.S. Steel by Japan's Nippon Steel, citing national security concerns
By Peter Weber, The Week US
-
Judges block $25B Kroger-Albertsons merger
Speed Read The proposed merger between the supermarket giants was stalled when judges overseeing two separate cases blocked the deal
By Peter Weber, The Week US